CHRIS AMOS to Neoadjuvant Therapy
This is a "connection" page, showing publications CHRIS AMOS has written about Neoadjuvant Therapy.
Connection Strength
0.110
-
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006 Aug 10; 24(23):3789-98.
Score: 0.053
-
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.
Score: 0.042
-
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann Surg Oncol. 2009 Feb; 16(2):431-9.
Score: 0.016